Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study

Psychopharmacology (Berl). 2000 Jun;150(2):132-40. doi: 10.1007/s002130000435.

Abstract

Rationale: Previous work suggests clozapine preferentially targets limbic cortical dopamine systems, which could help account for its lack of extrapyramidal side effects (EPS) and superior therapeutic efficacy.

Objectives: To test the hypothesis that olanzapine, a novel atypical antipsychotic drug, occupies temporal cortical D2/D3 receptors to a greater extent than striatal D2/D3 receptors in vivo.

Methods: Nine schizophrenic patients taking either olanzapine [(n=5; mean (SD) age: 32.5 (6.5) years; daily dose: 18.3 (2.6) mg] or sertindole [(n=4; mean (SD) age: 30.3 (7.4) years; daily dose: 16 (5.6) mg] were studied with [123I]epidepride ((S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenz amide) and single photon emission tomography (SPET). An estimate of [123I]epidepride 'specific binding' to D2/D3 receptors was obtained in patients and age-matched healthy volunteers. A summary measure was generated representing striatal and temporal cortical relative %D2/D3 receptor occupancy by antipsychotic drugs. Occupancy data were compared with previously studied groups of patients receiving typical antipsychotic drugs (n=12) and clozapine (n=10).

Results: Mean striatal and temporal cortical %D2/D3 receptor occupancy in olanzapine-treated patients was 41.3% (SD 17.9) and 82.8% (SD 4.2), respectively. Unexpectedly low levels of striatal relative %D2/D3 receptor occupancy were seen in two patients with typical antipsychotic-drug-induced movement disorder prior to switching to olanzapine. In the temporal cortex, mean D2/D3 dopamine receptor occupancy levels above 80% were seen for all antipsychotic drugs studied.

Conclusions: The atypical antipsychotic drugs olanzapine and sertindole, in common with clozapine, demonstrate higher occupancy of temporal cortical than striatal D2/D3 dopamine receptors in vivo at clinically useful doses. This could help mediate their atypical clinical profile of therapeutic efficacy with few extrapyramidal side effects. Limbic selective blockade of D2/D3 dopamine receptors could be a common action of atypical antipsychotic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / pharmacokinetics*
  • Benzamides / pharmacokinetics
  • Benzodiazepines
  • Corpus Striatum / metabolism
  • Female
  • Humans
  • Imidazoles / pharmacokinetics*
  • Indoles / pharmacokinetics*
  • Iodine Radioisotopes / pharmacokinetics
  • Male
  • Middle Aged
  • Olanzapine
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / pharmacokinetics
  • Pyrrolidines / pharmacokinetics
  • Receptors, Dopamine D2 / metabolism*
  • Receptors, Dopamine D3
  • Schizophrenia / metabolism
  • Temporal Lobe / metabolism
  • Tomography, Emission-Computed

Substances

  • Antipsychotic Agents
  • Benzamides
  • DRD3 protein, human
  • Imidazoles
  • Indoles
  • Iodine Radioisotopes
  • Pyrrolidines
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • epidepride
  • Benzodiazepines
  • Pirenzepine
  • sertindole
  • Olanzapine